company background image
NXG logo

NexgenRx TSXV:NXG Stock Report

Last Price

CA$0.25

Market Cap

CA$17.8m

7D

-3.8%

1Y

13.6%

Updated

21 Dec, 2024

Data

Company Financials

NXG Stock Overview

NexgenRx Inc. administers, adjudicates, and pays drug, dental, and other extended health-care claims for the beneficiaries of health benefit plans underwritten by its customers in Canada. More details

NXG fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance2/6
Financial Health6/6
Dividends2/6

My Notes

Capture your thoughts, links and company narrative

NexgenRx Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for NexgenRx
Historical stock prices
Current Share PriceCA$0.25
52 Week HighCA$0.34
52 Week LowCA$0.17
Beta0.36
1 Month Change-13.79%
3 Month Change-1.96%
1 Year Change13.64%
3 Year Change-35.90%
5 Year Change28.21%
Change since IPO-28.57%

Recent News & Updates

Recent updates

Optimistic Investors Push NexgenRx Inc. (CVE:NXG) Shares Up 45% But Growth Is Lacking

May 21
Optimistic Investors Push NexgenRx Inc. (CVE:NXG) Shares Up 45% But Growth Is Lacking

We Discuss Why NexgenRx Inc.'s (CVE:NXG) CEO Will Find It Hard To Get A Pay Rise From Shareholders This Year

May 10
We Discuss Why NexgenRx Inc.'s (CVE:NXG) CEO Will Find It Hard To Get A Pay Rise From Shareholders This Year

NexgenRx Inc.'s (CVE:NXG) Price Is Out Of Tune With Revenues

Mar 14
NexgenRx Inc.'s (CVE:NXG) Price Is Out Of Tune With Revenues

Here's Why We Think NexgenRx (CVE:NXG) Might Deserve Your Attention Today

Mar 07
Here's Why We Think NexgenRx (CVE:NXG) Might Deserve Your Attention Today

Is Now The Time To Put NexgenRx (CVE:NXG) On Your Watchlist?

Oct 18
Is Now The Time To Put NexgenRx (CVE:NXG) On Your Watchlist?

Does NexgenRx (CVE:NXG) Deserve A Spot On Your Watchlist?

Nov 30
Does NexgenRx (CVE:NXG) Deserve A Spot On Your Watchlist?

What NexgenRx Inc.'s (CVE:NXG) 32% Share Price Gain Is Not Telling You

Aug 24
What NexgenRx Inc.'s (CVE:NXG) 32% Share Price Gain Is Not Telling You

Here's Why NexgenRx Inc.'s (CVE:NXG) CEO May Have Their Pay Bumped Up

Jun 03
Here's Why NexgenRx Inc.'s (CVE:NXG) CEO May Have Their Pay Bumped Up

NexgenRx Inc.'s (CVE:NXG) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Feb 19
NexgenRx Inc.'s (CVE:NXG) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

How Much Is NexgenRx's (CVE:NXG) CEO Getting Paid?

Dec 28
How Much Is NexgenRx's (CVE:NXG) CEO Getting Paid?

Shareholder Returns

NXGCA InsuranceCA Market
7D-3.8%-0.8%-2.6%
1Y13.6%34.3%15.2%

Return vs Industry: NXG underperformed the Canadian Insurance industry which returned 34.3% over the past year.

Return vs Market: NXG underperformed the Canadian Market which returned 15.2% over the past year.

Price Volatility

Is NXG's price volatile compared to industry and market?
NXG volatility
NXG Average Weekly Movementn/a
Insurance Industry Average Movement2.7%
Market Average Movement8.1%
10% most volatile stocks in CA Market17.3%
10% least volatile stocks in CA Market2.9%

Stable Share Price: NXG's share price has been volatile over the past 3 months compared to the Canadian market.

Volatility Over Time: Insufficient data to determine NXG's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
2003n/aRon Louckswww.nexgenrx.com

NexgenRx Inc. administers, adjudicates, and pays drug, dental, and other extended health-care claims for the beneficiaries of health benefit plans underwritten by its customers in Canada. It offers NexSys claims management; NexAdmin plan administration; and NexPSPAssist patient support programs. The company also provides ancillary services.

NexgenRx Inc. Fundamentals Summary

How do NexgenRx's earnings and revenue compare to its market cap?
NXG fundamental statistics
Market capCA$17.78m
Earnings (TTM)CA$254.52k
Revenue (TTM)CA$16.11m

69.9x

P/E Ratio

1.1x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
NXG income statement (TTM)
RevenueCA$16.11m
Cost of RevenueCA$3.61m
Gross ProfitCA$12.50m
Other ExpensesCA$12.24m
EarningsCA$254.52k

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)0.0036
Gross Margin77.58%
Net Profit Margin1.58%
Debt/Equity Ratio0%

How did NXG perform over the long term?

See historical performance and comparison

Dividends

4.0%

Current Dividend Yield

279%

Payout Ratio

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/21 09:26
End of Day Share Price 2024/12/16 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

NexgenRx Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution